tiprankstipranks
Blurbs

Mizuho Securities Thinks Atara Biotherapeutics’ Stock is Going to Recover

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Atara Biotherapeutics (ATRAResearch Report), with a price target of $39.00. The company’s shares closed last Monday at $9.84, close to its 52-week low of $8.24.

According to TipRanks.com, Syed ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -13.8% and a 37.0% success rate. Syed covers the Healthcare sector, focusing on stocks such as Assembly Biosciences, Coherus Biosciences, and Unity Biotechnology.

Currently, the analyst consensus on Atara Biotherapeutics is a Strong Buy with an average price target of $35.80, which is a 275.3% upside from current levels. In a report issued on March 28, J.P. Morgan also maintained a Buy rating on the stock with a $22.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $20.04 and a one-year low of $8.24. Currently, Atara Biotherapeutics has an average volume of 1M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

Read More on ATRA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More